Novo Nordisk is currently progressing eleven drug candidates through clinical development, the most advanced of which are NN-9932 (semaglutide), CagriSema (cagrilintide + semaglutide), and cagrilintide, and are either in pre-registration or Phase III clinical trials (Table 2)
Reversing pathological neural activity using targeted plasticity
Acknowledgments All graphical illustrations in this work were prepared using BioRender ( Conflict of interest The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
This is due to easy convenience, high affordability, and improved patient compliance
Partnering with OMG lets me deliver results no competitor can touch and I have the labs to prove it
In addition to microglia, astrocytes and peripheral immune cells can also contribute to neuroinflammatory processes